ETC-1002 Lowers LDL-Cholesterol and Beneficially Modulates Other Cardio-Metabolic Risk Factors in Hypercholesterolemic Subjects†

Journal of Clinical Lipidology(2013)

引用 0|浏览11
暂无评分
摘要
Dr. Rosenberg is employed by Esperion Therapeutics.
更多
查看译文
关键词
hypercholesterolemic,ldl-cholesterol,cardio-metabolic
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要